The Endocrine Society's 95th Annual Meeting and Expo
The annual meeting of the Endocrine Society (ENDO 2013) was held from June 15 to 18 in San Francisco and attracted more than 9,300 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in endocrine and metabolic disorders. The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, growth hormone and sex steroid dysregulation, and thyroid cancer, and featured more than 3,000 scientific abstracts.
In one study, Louis Aronne, M.D., of Weill Cornell Medical College in New York City, and colleagues conducted an exploratory analysis to evaluate the effects of Belviq (lorcaserin hydrochloride) on blood glucose and lipid levels.
"Animal studies have demonstrated that Belviq's mechanism of action includes targeting the serotonin 5-HT2C pathway, with efficacy in improving glucose metabolism and reducing blood sugar levels," Aronne said. "Recent animal studies have shown that the serotonin 5-HT2C pathway has a direct effect on blood glucose metabolism, independent of the weight loss effect."
The investigators examined whether Belviq's impact on glucose levels could include an independent effect. Using a statistical approach, they evaluated the amount of blood sugar reduction and weight loss among patients who received Belviq versus those who received placebo.
"We found that the effects of Belviq on the serotonin 5-HT2C pathway had independent effects on blood sugar metabolism over and above that achieved through weight loss alone," Aronne added. "Our preliminary pilot analysis supports the findings of animal models. Further studies looking at this effect in humans with diabetes should be completed based on our preliminary results."
Several authors disclosed financial ties to pharmaceutical companies, including Arena Pharmaceuticals, the manufacturer of Belviq.
In another study, Paresh Dandona, M.D., Ph.D., of the State University of New York and Kaleida Health in Buffalo, and colleagues found that insulin resistance was elevated in patients with type 2 diabetes and low testosterone levels.
"It has been demonstrated that type 2 diabetes markedly increases the incidence and prevalence of low testosterone," Dandona said. "It has also been shown that low testosterone is associated with obesity. We previously found that 25 percent of patients with obesity had low testosterone that was independent of type 2 diabetes."
The investigators found that patients with type 2 diabetes and low testosterone had a 30 percent extra increase in insulin resistance. In addition, they also found that by giving these patients testosterone replacement for a period of six months, insulin resistance reverted back to normal levels. The investigators also identified anti-inflammatory effects associated with testosterone replacement.
"One-third of patients with type 2 diabetes have low testosterone and this defect is not at the testicular level but in the hypothalamus, a part of the brain," Dandona added. "In addition, six months of testosterone therapy not only reverses insulin resistance but it also causes a reduction in body fat by 2 kilograms and its replacement by lean body mass (muscle). Finally, it also causes the suppression of body inflammation known to occur in obesity and type 2 diabetes."
In an animal study, Suzanne Wardell, Ph.D., of Duke University in Durham, N.C., and colleagues found that Conbriza (bazedoxifene) was effective in hindering growth of estrogen-sensitive cancer resistant to tamoxifen. The investigators used human-derived breast cancer cell lines that were resistant to tamoxifen, aromatase inhibitors, and lapatinib and then transplanted these cultured breast tumors into immune-compromised mice and found that Conbriza inhibited estrogen receptor-dependent tumor growth.
"Bazedoxifene, a known, safe drug approved in Europe, may present a near-term option as an effective therapy for breast cancer in patients who have relapsed during treatment with tamoxifen or aromatase inhibitors," Wardell said in a statement.
Several authors disclosed financial ties to Pfizer, the manufacturer of Conbriza.
ENDO: MR Antagonist Counters Metabolic Dysfunction in Mice
WEDNESDAY, June 19 (HealthDay News) -- Mineralocorticoid receptor (MR) antagonists can counter high-fat (HF)-diet-induced metabolic dysfunction in mice, according to an experimental study presented at the annual meeting of The Endocrine Society, held from June 15 to 18 in San Francisco.
ENDO: Testosterone Beneficial After Surgical Menopause
WEDNESDAY, June 19 (HealthDay News) -- For surgically menopausal women, testosterone administration correlates with improvements in several domains of sexual function, with evidence of a dose-dependent effect, according to a study presented at the annual meeting of The Endocrine Society, held from June 15 to 18 in San Francisco.
ENDO: Catching Up on Sleep Improves Insulin Sensitivity
TUESDAY, June 18 (HealthDay News) -- For men with chronic, intermittent sleep restriction, three nights of weekend sleep extension correlate with improved insulin sensitivity, according to a study presented at the annual meeting of The Endocrine Society, held from June 15 to 18 in San Francisco.
ENDO: INSL33 Levels Decreased in Cryptorchidism
MONDAY, June 17 (HealthDay News) -- Insulin-like peptide 3 (INSL3) levels are decreased in cryptorchidism and correlate negatively with bisphenol A (BPA), according to a study presented at the annual meeting of The Endocrine Society, held from June 15 to 18 in San Francisco.
ENDO: Skipping Breakfast Tied to Insulin Resistance in Obese
MONDAY, June 17 (HealthDay News) -- In overweight or obese women, missing breakfast is associated with insulin resistance, according to a study presented at the annual meeting of The Endocrine Society, held from June 15 to 18 in San Francisco.